

**FOI 3197**

21<sup>st</sup> July 2025

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**Question: I am analysing the usage of new biologic and targeted medications within dermatology and respiratory medicine. Could you please answer the following questions:**

**How many patients were treated in June 2025 (or latest available month) by the Dermatology department with the following drugs:**

**Response:**

<b>Specific Drug</b>	<b>Total number of patients</b>
<b>Abrocitinib (Cibinqo)</b>	2
<b>Baricitinib (Olumiant)</b>	1
<b>Dupilumab (Dupixent)</b>	128
<b>Lebrikizumab (Ebglyss)</b>	3
<b>Omalizumab (Xolair)</b>	37
<b>Tralokinumab (Adtralza)</b>	1
<b>Upadacitinib (Rinvoq)</b>	45
<b>Nemolizumab (Nemluvio)</b>	0

**Question: How many patients were treated in June 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs:**

- **Benralizumab (Fasenra)**
- **Dupilumab (Dupixent)**
- **Mepolizumab (Nucala)**
- **Omalizumab (Xolair)**
- **Reslizumab (Cinqaero)**
- **Tezepelumab (Tezspire)**

**Response:**

No patients within Respiratory were treated with the medications listed above in June 2025. This is a tertiary level service, and all patients deemed potentially appropriate are referred to BHSCT for consideration.